NasdaqGM:ZLABBiotechs
A Look At Zai Lab (NasdaqGM:ZLAB) Valuation As UBS Initiates Coverage And Highlights Global Pipeline Shift
UBS recently initiated coverage on Zai Lab (NasdaqGM:ZLAB), highlighting the company’s shift from a China focused commercial model toward a broader global innovation platform and renewed attention on its cancer and immunology pipeline.
See our latest analysis for Zai Lab.
Despite the UBS coverage putting fresh attention on Zai Lab, the share price has come under pressure, with a 90 day share price return of a 35.88% decline and a 1 year total shareholder return of a 39.37% decline, signaling...